外周血管介入器械行业深度报告：集采正推进，国内品牌大有可为

Investment Rating - The report maintains a "Buy" rating for the peripheral vascular intervention device industry, highlighting significant growth potential due to increasing domestic brand participation in the market [8]. Core Insights - The peripheral vascular disease market in China is characterized by a large patient population and low intervention penetration, indicating substantial unmet clinical needs [8][49]. - The report emphasizes the ongoing national procurement initiatives that are expected to accelerate the entry of domestic brands into hospitals, enhancing their market presence [8][49]. - The projected growth rates for peripheral vascular intervention surgeries are significant, with estimates of 15.6% CAGR for arterial procedures and 25.3% CAGR for venous procedures from 2021 to 2030 [49][52]. Summary by Sections Industry Overview - Peripheral vascular intervention primarily addresses diseases outside of the heart and brain, with a focus on peripheral artery and vein diseases [15]. - The prevalence of peripheral artery disease (PAD) is notable, with approximately 6% of adults globally affected, and the majority of cases being lower extremity artery disease (LEAD) [17][19]. Market Dynamics - The report identifies a substantial patient base for peripheral vascular diseases, with over 52 million individuals suffering from peripheral artery disease in China as of 2021, projected to increase to 62 million by 2030 [46]. - The intervention rates for both peripheral artery and vein diseases are currently below 1%, indicating a significant opportunity for growth as awareness and healthcare capabilities improve [49][52]. Competitive Landscape - The market is currently dominated by foreign companies, but domestic brands are expected to gain traction due to favorable procurement policies and increasing product approvals [8][49]. - Key companies to watch in the peripheral vascular intervention space include Xinmai Medical, Huatai Medical, Xianjian Technology, Guichuang Tongqiao-B, and Xianruida Medical-B, all of which are well-positioned to benefit from the ongoing market changes [8].